Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInvested CapitalOperating MarginReturn on AssetsReturn on Capital EmployedReturn on Equity

Seres Therapeutics (MCRB) EBT Margin (2016 - 2025)

Historic EBT Margin for Seres Therapeutics (MCRB) over the last 9 years, with Q3 2025 value amounting to 6227.64%.

  • Seres Therapeutics' EBT Margin changed N/A to 6227.64% in Q3 2025 from the same period last year, while for Sep 2025 it was 28834.76%, marking a year-over-year increase of 1658839900.0%. This contributed to the annual value of 150.61% for FY2023, which is 24149900.0% up from last year.
  • Latest data reveals that Seres Therapeutics reported EBT Margin of 6227.64% as of Q3 2025.
  • In the past 5 years, Seres Therapeutics' EBT Margin ranged from a high of 53.86% in Q3 2021 and a low of 54770.31% during Q4 2023
  • Over the past 4 years, Seres Therapeutics' median EBT Margin value was 1741.26% (recorded in 2022), while the average stood at 7800.15%.
  • Within the past 5 years, the most significant YoY rise in Seres Therapeutics' EBT Margin was 53366000bps (2023), while the steepest drop was -545449800bps (2023).
  • Seres Therapeutics' EBT Margin (Quarter) stood at 688.06% in 2021, then skyrocketed by 67bps to 225.33% in 2022, then crashed by -24206bps to 54770.31% in 2023, then skyrocketed by 89bps to 6227.64% in 2025.
  • Its last three reported values are 6227.64% in Q3 2025, 54770.31% for Q4 2023, and 13552.9% during Q3 2023.